Abstract Medulloblastoma (MB) is a malignant paediatric brain tumor comprised of 4 molecularly and clinically distinct subgroups: WNT, SHH, Group 3 4. Previous studies have reported recurrent, mutually exclusive epigenetic modifier mutations converging in these subgroups, as well aberrant H3K27me3 depositions within tumors. While observations hint at mechanisms driving MB pathobiology, detailed...